ES2196864T3 - Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1. - Google Patents

Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.

Info

Publication number
ES2196864T3
ES2196864T3 ES99948807T ES99948807T ES2196864T3 ES 2196864 T3 ES2196864 T3 ES 2196864T3 ES 99948807 T ES99948807 T ES 99948807T ES 99948807 T ES99948807 T ES 99948807T ES 2196864 T3 ES2196864 T3 ES 2196864T3
Authority
ES
Spain
Prior art keywords
icam
sequence
antisentide
molecula
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99948807T
Other languages
English (en)
Inventor
Volker Patzel
Ralf Kronenwett
Ulrich Steidl
Rainer Haas
Georg Sczakiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19844111A external-priority patent/DE19844111A1/de
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2196864T3 publication Critical patent/ES2196864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Acido nucleico antisentido, que está dirigido por ICAM-1 contra una secuencia específica de ácidos nucleicos y que consta como mínimo de una de las secuencias de ácidos nucleicos caracterizadas por al menos una de SEC ID N° 1-12, 15, 29 y 30.
ES99948807T 1998-09-25 1999-09-21 Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1. Expired - Lifetime ES2196864T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19844111A DE19844111A1 (de) 1998-09-25 1998-09-25 Antisense-Sequenzen für die Hemmung der Expression des Adhäsionsmoleküls ICAM-1
DE19856138 1998-12-04
DE19926110 1999-06-08

Publications (1)

Publication Number Publication Date
ES2196864T3 true ES2196864T3 (es) 2003-12-16

Family

ID=27218700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99948807T Expired - Lifetime ES2196864T3 (es) 1998-09-25 1999-09-21 Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.

Country Status (6)

Country Link
EP (1) EP1115858B1 (es)
AT (1) ATE236250T1 (es)
AU (1) AU6193699A (es)
DE (1) DE59904870D1 (es)
ES (1) ES2196864T3 (es)
WO (1) WO2000018907A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
WO2011109810A2 (en) 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
GB201700261D0 (en) * 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New therapeutic uses
GB201700257D0 (en) 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New formulation
EP3658154B1 (en) * 2017-07-28 2024-07-10 Universität zu Lübeck Antisense drugs against canine icam-1 for use in the treatment of inflammation of the buccal cavity
WO2020151881A1 (en) * 2019-01-25 2020-07-30 Universität Zu Lübeck Antisense drug against the human intercellular adhesion molecule 1 (icam-1)
EP3685824A1 (en) * 2019-01-25 2020-07-29 Breitenbronn-Consulting GbR Composition for administering and releasing oligonucleotides
US20250297247A1 (en) * 2021-12-09 2025-09-25 Splisense Ltd. Muc5ac-targeted antisense oligonucleotides and related methods for modulating mucin expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0178958B1 (ko) * 1992-09-02 1999-03-20 데이비드 제이.엑커 세포 흡착의 올리고누클레오티드 조절
EP0755402B1 (en) * 1994-04-13 2008-05-14 Biotransplant, Inc Alpha(1,3) galactosyltransferase negative swine
JP2001505432A (ja) * 1996-12-02 2001-04-24 ダイヤド ファーマシューティカル コーポレイション ヒト接着分子のアンチセンス阻害

Also Published As

Publication number Publication date
DE59904870D1 (de) 2003-05-08
WO2000018907A2 (de) 2000-04-06
AU6193699A (en) 2000-04-17
ATE236250T1 (de) 2003-04-15
WO2000018907A3 (de) 2000-06-29
EP1115858A2 (de) 2001-07-18
EP1115858B1 (de) 2003-04-02

Similar Documents

Publication Publication Date Title
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
ES2182791T3 (es) Procedimiento y medicamento para la inhibicion de la expresion de un gen predeterminado.
BR9908280A (pt) Inibidores de enzimas de fosfolipase
BR9902457A (pt) Padrões de adesivo aperfeiçoados para artigos de higiene feminina.
ES2196864T3 (es) Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
ES2133727T3 (es) Derivados de acido hidroxamico como inhibidores de metaloproteinasa.
AR015837A1 (es) Metodo de transformacion de plantas.
CY1106041T1 (el) Καινοφανης συλλεκτινη
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
BR9907746A (pt) ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
DE60104687D1 (de) Mikrofiltration unter verwendung von aktivkohle
ES2183313T3 (es) Carbonatos para la generacion de aldehidos y/o cetonas.
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
BR0001342A (pt) Processo para a produção de l-aminoácidos por meio de fermentação usando bactérias corineformes
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
MA25342A1 (fr) 2,3,-o-derives d'isopropylidene de monosaccharides utilises en tant qu'inhibiteurs d'adhesion de cellules.
BR0002493A (pt) Processo para a preparação de l-aminoácidos por fermentação e sequências de nucleotìdeos que codificam o gene accda
BR0313550A (pt) modulação "antisense" da expressão de sintetase 1 de acil-coa
BR9808554A (pt) Esterase do ácido fenólico e o uso da mesma
WO1997046673A3 (en) Inhibition of hiv-1 replication by antisense rna expression
BR0012565A (pt) Método de função de correlação de sequência pela transfecção de uma das sequências de ácido nucleico de um organismo doador em um hopedeiro de planta em uma orientação de sentido positivo ou anti-sentido
BR9909700A (pt) Oligonucleotìdeos anti-sentidos para a inibição de expressão de subunidade alfav de integrina
EP1064402A4 (en) ANTISENSE MODULATION OF LFA-3